证券日报网讯12月2日，双鹭药业（002038）在互动平台回答投资者提问时表示，公司始终高度重视信 息披露工作，严格遵守上市规则，所有公告均依法依规进行。 ...

Core Viewpoint - The company has a range of antiviral and immune-enhancing products in its portfolio, including those for influenza treatment and prevention, as well as innovative drugs in development [1] Group 1: Current Products - The company offers Oseltamivir and Clindamycin as antiviral medications for influenza [1] - Immune-enhancing agents in the company's product line include Thymosin Alpha 1 and Interleukin-2 [1] Group 2: Innovative Drug Development - The company is developing innovative drugs such as Long-acting Follicle Stimulating Hormone and DT-678 [1]

Core Viewpoint - The company, Shuanglu Pharmaceutical, has a diverse product portfolio that includes not only Oseltamivir but also Clindamycin and various immune enhancers such as Thymosin Alpha-1 and Interleukin-2, along with innovative drugs currently under development like Long-acting Follicle Stimulating Hormone and DT-678 [1] Product Portfolio - The company offers a range of products including Oseltamivir and Clindamycin [1] - Immune enhancers in the company's portfolio include Thymosin Alpha-1 and Interleukin-2 [1] Innovative Drug Development - The company is developing innovative drugs such as Long-acting Follicle Stimulating Hormone and DT-678 [1]

Group 1 - The core viewpoint of the article is that Shuanglu Pharmaceutical (002038.SZ) has seen an increase in orders for Oseltamivir and is closely monitoring the sales performance of this drug alongside other antiviral medications [1] Group 2 - The company is actively engaging with investors through an interactive platform to provide updates on its product sales [1] - There is a specific focus on the sales situation of Oseltamivir in relation to other anti-influenza drugs [1]

Group 1 - The core viewpoint of the article is that Shuanglu Pharmaceutical (002038.SZ) has seen an increase in orders for Oseltamivir and is closely monitoring the sales performance of this drug alongside other antiviral medications [1] Group 2 - The company is actively engaging with investors through an interactive platform to provide updates on its product sales [1] - There is a specific focus on the sales situation of Oseltamivir in relation to other anti-influenza drugs [1]

Core Viewpoint - The company, Shuanglu Pharmaceutical, emphasizes the advantages of its exclusive nitroglycerin spray, which is designed for emergency treatment of angina and is included in the national medical insurance directory [1] Group 1: Product Advantages - The nitroglycerin spray is more convenient to use, acts faster, and has a higher safety profile compared to traditional forms [1] - The product can be absorbed directly through the oral mucosa without the need for dissolution, typically taking effect within 30 seconds to 1 minute [1] Group 2: Market Context - There has been a rising incidence of sudden cardiac death and myocardial infarction, particularly among younger individuals, attributed to high stress, irregular diet, and lifestyle [1] - The nitroglycerin spray is positioned as a household emergency medication for patients with angina [1] Group 3: Marketing Strategy - The company is increasing its promotional efforts and strengthening collaborations with various pharmaceutical sales channels to enhance market coverage [1] - The goal is for the nitroglycerin spray to become a key product for the company in the future [1]

Group 1: Impact of National Drug Procurement - The company has been significantly affected by the 8th and 9th batches of national drug procurement, with major products entering procurement and experiencing price reductions of up to 70% [2][3] - Temozolomide capsules saw a price drop of 62% during the 4th batch procurement, yet sales revenue increased by 109% despite the price cut [5][6] - The average price of several biological products decreased by approximately 15% due to regional alliance procurement [3] Group 2: Business Model and Product Structure - The company operates as a biopharmaceutical enterprise, covering drug research, production, and marketing, with a focus on expanding into the health sector [4] - The product structure has shifted from a high reliance on major products to a more diversified portfolio, enhancing risk resistance [6][11] - Oral solid preparations now account for over 50% of the product mix, reflecting a significant change from previous years when injectables dominated [12] Group 3: New Product Launches and Profit Contribution - The contribution of new and upcoming products to profits depends on their procurement success and market expansion of non-procurement products [6] - The company has a rich pipeline of new products, indicating a potential shift towards a multi-product profit model [6] Group 4: Production Capacity and Operations - The company has eight major production bases, with some operating at full capacity and others reserved for future product launches [7] - Plans are in place to transfer some production to lower-cost locations to participate in larger-scale procurement [7] Group 5: Sales Performance and Key Products - The top ten products by sales revenue in the first three quarters of 2025 include: - Fuzhifu: 59.6 million CNY - Temozolomide capsules: 55.2 million CNY - Oseltamivir phosphate capsules: 52.7 million CNY [8] - Changes in invoicing models have affected reported sales revenue, complicating the assessment of actual sales performance [8] Group 6: International Investments and Collaborations - The company holds a 30% stake in Diapin Therapeutics, focusing on innovative drug development for diabetes and cardiovascular diseases [9] - ATGC Company is developing a unique therapeutic antibody platform using genetically modified rabbits, with significant progress reported [10] Group 7: Market Position and Stock Performance - The company has faced a prolonged adjustment period due to policy changes and competitive pressures, with market capitalization remaining below 10 billion CNY for years [13] - Management emphasizes the importance of developing competitive products to improve performance and shareholder returns [13] Group 8: Recent Investments - The company invested 10 million CNY in Changfeng Pharmaceutical, which is now publicly listed, holding a 3.68% stake valued at nearly 500 million CNY [15] - The investment in Xuan Bamboo Biotechnology also resulted in a public listing, with a 0.34% stake valued at approximately 206 million CNY [15]

Group 1: Company Performance and Market Impact - The company's main business revenue decreased by 15.40% year-on-year in the first three quarters of 2025, influenced by significant price drops in key products due to national drug procurement policies [3][4] - Products entering national procurement saw price reductions exceeding 50%, while those in provincial and local procurement experienced an average price drop of around 15% [3] - Key products like Lenalidomide and Metronidazole have dropped out of the top ten revenue-generating products, indicating a shift in the company's revenue sources [3] Group 2: New Product Developments - Recent new products that won national procurement include Voriconazole tablets and Vildagliptin tablets, which are becoming mainstay products for the company [4] - The company has also introduced a unique dosage form of Nitroglycerin spray, which has good market potential and is now available for purchase [7][9] - The company is developing several new drugs, including GLP-1 formulations for diabetes treatment, which are in the final stages of clinical research [11] Group 3: Investment Activities - The company invested 10 million yuan in Changfeng Pharmaceutical in 2010, which is now valued at nearly 500 million yuan following its listing on the Hong Kong Stock Exchange [5] - The company holds a 20% stake in Beijing Hengtai Kang Pharmaceutical Technology Co., which is developing a unique probiotic lozenge [7] - The company prefers equity investments in promising firms rather than acquisitions, to avoid burdening its operational focus [12] Group 4: Sales and Marketing Strategies - The company has shifted from a primarily hospital-based sales model to include e-commerce platforms, with online sales increasing year by year [10] - Efforts are being made to enhance product market penetration and expand sales channels, particularly through partnerships with various pharmaceutical sales platforms [10] Group 5: Future Outlook - The company anticipates that the impact of price reductions from national procurement will weaken if no major products enter procurement in the near future [12] - There is a need for increased R&D efforts and faster product launches to boost main business revenue moving forward [12]

Group 1 - The core viewpoint of the news is that Shuanglu Pharmaceutical's stock has been declining for four consecutive days, with a total drop of 4.96% during this period, leading to a current stock price of 7.28 CNY per share and a market capitalization of 7.479 billion CNY [1] - Shuanglu Pharmaceutical, established on December 24, 1994, and listed on September 9, 2004, focuses on the research, development, and production of gene-engineered and related drugs, with its main business revenue composition being 56.82% from chemical drugs, 39.41% from biological and biochemical drugs, and 2.52% from other sources [1] - The trading volume for Shuanglu Pharmaceutical reached 98.4236 million CNY, with a turnover rate of 1.55% [1] Group 2 - Among the top ten circulating shareholders of Shuanglu Pharmaceutical, Huaxia Fund's Huaxia CSI 1000 ETF (159845) has recently entered the list, holding 3.9085 million shares, which accounts for 0.46% of the circulating shares [2] - The Huaxia CSI 1000 ETF has experienced a floating loss of approximately 152.43 thousand CNY today and a total floating loss of 156.34 thousand CNY during the four-day decline [2] - The Huaxia CSI 1000 ETF was established on March 18, 2021, with a current scale of 45.469 billion CNY, and has achieved a year-to-date return of 24.61% [2]

Core Viewpoint - Recent data indicates a significant rise in influenza activity in China, with a notable increase in patients visiting hospitals for treatment, prompting the need for early antiviral therapy and consideration of various factors in drug selection [1][2][3] Group 1: Influenza Activity - The latest report from the Chinese Center for Disease Control and Prevention shows a marked increase in influenza activity, particularly in southern provinces, with the percentage of influenza-like illness (ILI) cases reported at 4.6%, up from 4.1% the previous week [2] - Northern provinces reported an ILI percentage of 5.1%, significantly higher than the previous week's 3.7% and above levels from 2022, 2023, and 2024 [2] - A total of 347 influenza-like illness outbreaks were reported nationwide, with 245 cases identified as A(H3N2) [2] Group 2: Treatment and Drug Approval - The increase in influenza cases has led to a rise in hospital visits, particularly in pediatric departments, with doctors recommending early antiviral treatment within 48 hours of symptom onset [4] - Oseltamivir remains the preferred antiviral treatment, especially for children and immunocompromised patients, with over 120 approvals for related products from various companies [4][5] - The market for oseltamivir is dominated by Dongyangguang Pharmaceutical, holding over 70% market share in the past three years [4] Group 3: New Drug Developments - Several new RNA polymerase inhibitors have been approved in China, with the year 2025 being referred to as the "Year of Domestic Influenza New Drugs" [1][6] - Roche's Marbofloxacin has seen a significant increase in demand, with supply pressures leading to local production initiatives [6][7] - Other domestic companies, such as Qingfeng Pharmaceutical and Zhongsheng Pharmaceutical, have also launched new antiviral drugs, contributing to a broader range of treatment options for influenza [7][8] Group 4: Market Dynamics - The price of Marbofloxacin ranges from 195 to 234 yuan per pack, with no adjustments made by Roche despite increased demand [7] - Companies like Haizheng Pharmaceutical have reported a significant rise in demand for their antiviral products, with ongoing supply guarantees in place [8][9] - The market is seeing increased competition as more domestic firms enter the RNA polymerase inhibitor space, with several products currently in clinical trials or awaiting approval [9]